An international team led by researchers at Harvard Medical School and Massachusetts General Hospital has devised a new way to approach the problem of multidrug-resistant fungal infections that can be life-threatening to people with weakened immune systems.
RPB Stein Innovation Awards provide funds to researchers in the ophthalmology department and to basic science or other relevant vision researchers outside of the ophthalmology department (but within the institution) with a common goal of understanding the visual system and the diseases that compromise its function.
The AAA-ATPase VCP (also known as p97 or CDC48) uses ATP hydrolysis to ‘segregate’ ubiquitylated proteins from their binding partners, and has been implicated in numerous pathways ranging from ERAD to repair of damaged DNA.
Allied-Bristol Life Sciences, a joint venture between the university commercialization specialist Allied Minds and the US pharmaceutical company Bristol-Myers Squibb, is licensing research carried out by Malcolm Whitman on halofuginone, an active ingredient in blue evergreen hydrangea root.
Current and recent members of the Van Vactor and Perrimon laboratories at HMS have created a transgenic resource to allow conditional analysis of in vivo functions for over 140 microRNA genes in Drosophila with spatial and temporal precision.
Using a combination of live cell imaging and single cell genome sequencing (Look-Seq), the Pellman laboratory has defined a mechanism for a new mutational process in cancer and congenital disease called chromothripsis (Zhang et al., Nature, 2015).
Congratulations to Tobi Walter, who was chosen from a group of 894 eligible applicants to be one of 26 newly-minted Howard Hughes Medical Institute (HHMI) Investigators!
